The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...
HealthDay on MSN1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of TreatmentTHURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...
Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...
Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback